Clinical and analytical performance of the PapilloCheck HPV-Screening assay using the VALGENT framework.

Last updated on 22-8-2019 by Anonymous (not verified)

Peer reviewed scientific article




BACKGROUND: The benefit of HPV testing for cervical cancer screening and disease management has been shown in many recent studies and is part of several new evidence-based guidelines. Assessment of emerging HPV tests in this context is essential, using well-annotated samples, such as those generated via the Validation of Genotyping Tests-HPV (VALGENT) framework.OBJECTIVE: Our aim was to assess the PapilloCheck HPV assay in terms of absolute and relative accuracy for primary cervical cancer screening, using a standard comparator test (GP5+/6+EIA)already validated in randomised trials.STUDY D…

Associated health topics:

QR code

QR code for this page URL